

SUBJECTIVE: Patient arrives for scheduled Cycle 5, Day 1 of Carboplatin/Pemetrexed/Pembrolizumab. Reports feeling well since last cycle 3 weeks ago. Had mild fatigue for ~48 hours post-C4, resolved. No nausea, vomiting, diarrhea, rash. Denies headaches, seizures, vision changes, or other neurological symptoms. Appetite good. Energy levels allow her to work part-time and manage household activities. Receiving B12 injection today, compliant with daily Folic Acid.

PERTINENT HISTORY: Dx Stage IV Lung Adeno March 17, 2023 (presented w/ headache). Brain MRI showed solitary L cerebellar metastasis (1.2cm) + edema. CT C/A/P showed 2cm RUL primary + mediastinal nodes. No other mets. Underwent SRS to brain lesion March 25, 2023. Pathology: Adenocarcinoma, NGS WT, PD-L1 (22C3) **TPS 20%, CPS 25, IC 1/+**. Started 1L Carbo (AUC 5)/Pem (500mg/m²)/Pembro (200mg) April 7, 2023. On Dexamethasone taper post-SRS, completed May 2023.

OBJECTIVE:

- Vitals: Stable, WNL. ECOG PS 0.
- Exam: NAD. Neuro exam non-focal. Lungs clear.
- Labs (Pre-Chemo): CBC: WBC 8.2 (ANC 5.1), Hgb 11.8, Plt 310k. CMP: Cr 0.7, LFTs WNL. TSH normal. (Counts/renal/hepatic function adequate for chemo).
- Recent Imaging (August 15, 2023):
 - Brain MRI: Stable post-SRS changes L cerebellum, no new/recurrent intracranial disease. Edema resolved.
 - CT C/A/P: Partial response ongoing. RUL primary stable at 0.8cm (down from 2cm). Mediastinal nodes regressed further, now borderline size. Stable compared to prior scan (June 2023).

ASSESSMENT: Stage IV WT Lung Adeno (PD-L1 20%) responding well to 1L Carbo/Pem/Pembro. Brain met stable post-SRS. Tolerating chemo/IO well. Fit for Cycle 5 today.

PLAN:

1. Administer C5D1: Carboplatin AUC 5 IV, Pemetrexed 500mg/m² IV, Pembrolizumab 200mg IV.
2. Standard pre-meds (Dex 12mg IV, Ondansetron 16mg IV, +/- Aprepitant PO per protocol). IV hydration.
3. Received B12 1000mcg IM today. Continue Folic Acid 1mg daily.
4. Next Cycle (C6D1 - final planned Carbo cycle) in 3 weeks. Plan transition to Pem/Pembro maintenance thereafter.
5. Next scans ~2 cycles after transitioning to maintenance (approx. Dec 2023).
6. Continue monitoring for chemo & IO toxicities. Reviewed IR-AE precautions.
7. Patient has anti-emetic Rx (Ondansetron PRN) at home.

Infusion tolerated without immediate reaction. Discharged home in stable condition.

Signatures: K. Patel, RN, OCN / V. Wells, MD

Patient: Aniston, Linda

MRN: SYN054 **DOB:** 10/23/1969

Date: August 25, 2023

Visit: Chemo Infusion C5D1 (Carbo/Pem/Pembro)

Provider: K. Patel, RN, OCN / V. Wells, MD (Supervising)